HSBC Multi Cap Fund
The scheme seeks to generate long-term capital growth from an actively managed portfolio of equity and equity related securities across market capitalization.
Growthvine rating: 4/5 — ranked #4 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹20.53 (as of 2026-08-21) |
|---|
| AUM | ₹5,914 Cr |
|---|
| Expense ratio | 1.57% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Venugopal Manghat |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Sharpe ratio | 0.72 |
|---|
| Standard deviation | 17.38% |
|---|
| Max drawdown | -20.28% |
|---|
| Alpha | 5.76 |
|---|
| Beta | 1.02 |
|---|
Over 5 years, captured 108.0% of NIFTY500 Multicap 50:25:25's upside and 94.7% of its downside.
Market cap allocation
| Large cap | 41.4% |
|---|
| Mid cap | 27.3% |
|---|
| Small cap | 31.3% |
|---|
Concentration
| Top 5 holdings | 12.6% |
|---|
| Top 10 holdings | 21.7% |
|---|
| Total holdings | 101 |
|---|
| Index overlap | 35.7% |
|---|
| Active share | 64.3% |
|---|
Top holdings
- HDFC Bank Ltd. — 3.2%
- Federal Bank Ltd. — 2.8%
- ICICI Bank Ltd. — 2.4%
- Reliance Industries Ltd — 2.2%
- State Bank Of India — 2.0%
- Radico Khaitan Ltd. — 1.9%
- Sai Life Sciences Limited — 1.9%
- Treps — 1.9%
- Navin Fluorine International Limited — 1.8%
- Apar Industries Ltd — 1.8%
Top sectors
- Banking & Financial — 21.1%
- Pharma & Biotech — 9.1%
- Industrial Products — 8.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 8.1% | Q2 | #14 of 34 |
| 2025 | 1.1% | Q3 | #24 of 31 |
| 2024 | 28.6% | Q2 | #7 of 24 |